Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) after a surprising shift in analyst sentiment? Latest Ratings for REGN Date Firm Action From To Feb 2022 Truist Securities Maintains Buy Feb 2022 Oppenheimer Maintains Outperform Feb 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for REGN View the Latest Analyst Ratings read more